Physician profile
Ying Du
NPI 1295725182
$14,081.78
in general payments reported to CMS, 2019-2025
55 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,230 · 2020: $1,045 · 2021: $2,005 · 2022: $2,248 · 2023: $3,095 · 2024: $2,303 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,546 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,545.99 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,794.37 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $2,083.16 | 2019-2025 | Rinvoq, Skyrizi, Ubrelvy |
| Pfizer INC. | $1,334.89 | 2019-2025 | |
| Ucb, INC. | $1,293.05 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $848.07 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $593.25 | 2020-2025 | Taltz, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $544.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $450.44 | 2020-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $406.96 | 2021-2025 | Saphnelo, Evusheld, Flumist Quadrivalent |
| Novo Nordisk INC | $369.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Horizon Therapeutics Plc | $337.89 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.24 | 2021-2025 | Cyltezo, Ofev |
| Sandoz INC. | $281.34 | 2023-2024 | Hyrimoz |
| Amarin Pharma, INC. | $246.71 | 2019-2021 | |
| Celgene Corporation | $234.27 | 2019 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ying Du listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.